

# Specimen SPECT for Intra-operative Assistance in Radio-guided Surgery

Kathiresan Chandrasekaran
 (M. Sc. Biomedical Engineering and Medical Physics)

Supervisor 1: Dr. Thomas Wendler

Supervisor 2: Berkay Cakal, M.Sc.

**Director:** Prof. Dr. Nassir Navab










## **Table of Contents:**


- Introduction
- Motivation / Problem statement
- . Relevant research works
- Proposed solution overview
- Technical aspects (RGBD and SPECT)

## **Introduction**


- Prostate cancer is the 4th most common cancer overall and the 2nd most commonly occurring cancer in men. [1]
- The count of prostate cancer patients surpasses other deadliest cancer types since 2014. [2]



UK prostate and breast cancer deaths, 1999-2015




Source: Prof. Christopher Eden, Refer [x]





# **Introduction**

• General treatment: **Radical Prostatectomy** (removal of entire prostate cancer tissue). [3]



Confirmation of "resection margin" is required during surgery. [3]




Figure 2: Resection Margin




# **Motivation / Problem statement**

- Problem 1: Requirement of a Pathologist in the OR. [3]
- Problem 2: Time consuming for sample preparation. [4]
- Problem 3: Prostate tissue undergoes faster autolysis than most of the other organs. [5]


[3] Montironi R, van der Kwast T, Boccon-Gibod L, Bono AV, Boccon-Gibod L, Handling and pathology reporting of radical prostatectomy specimens, Eur Urol, 2003 Dec;44(6):626-36, doi: 10.1016/s0302-2838(03)00381-6. PMID: 14644113.

[4] Jorns JM, Visscher D, Sabel M, Breslin T, Healy P, Daignaut S, Myers JL, Wu AJ. Intraoperative frozen section analysis of margins in breast conserving surgery significantly decreases reoperative rates: one-year experience at an ambulatory surgical center. Am J Clin Pathol. 2012 Nov:138(5):657-69. doi: 10.1309/AJCP4IEMXCJ1GDTS. PMID: 23086766: PMCID: PMC3988579.







[CT: Computed Tomography; OCT: Optical Coherence Tomography; MRI: Magnetic Resonance Imaging; ESS: Elastic Scattering Spectroscopy]




[CT: Computed Tomography; OCT: Optical Coherence Tomography; MRI: Magnetic Resonance Imaging; ESS: Elastic Scattering Spectroscopy]



[CT: Computed Tomography; OCT: Optical Coherence Tomography; MRI: Magnetic Resonance Imaging; ESS: Elastic Scattering Spectroscopy]



[CT: Computed Tomography; OCT: Optical Coherence Tomography; MRI: Magnetic Resonance Imaging; ESS: Elastic Scattering Spectroscopy]




[CT: Computed Tomography; OCT: Optical Coherence Tomography; MRI: Magnetic Resonance Imaging; ESS: Elastic Scattering Spectroscopy]

#### **Optical** imaging **PET** imaging Advantages: Disadvantages: Advantages: Disadvantages: • High-throughput screening Clinical translation Limited clinical Cost for target confirmation and · High sensitivity with translation compound optimization · Low depth unlimited depth High sensitivity penetration penetration **SPECT imaging** Magnetic resonance imaging Disadvantages: Disadvantages: Advantages: Advantages: Clinical translation Clinical translation Costs Limited spatial resolution • High resolution and · Imaging time Unlimited depth soft-tissue contrast penetration **Ultrasound imaging CT** imaging Disadvantages: Advantages: Disadvantages: Advantages: Operator dependency Clinical translation High spatial resolution No target-specific High spatial and Targeted imaging (bone/lung) imaging Clinical translation temporal resolution limited to vascular Radiation Low costs Poor soft-tissue contrast compartment



[7] Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008 Jul;7(7):591-607. doi: 10.1038/nrd2290. PMID: 18591980.





[7] Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008 Jul;7(7):591-607. doi: 10.1038/nrd2290. PMID: 18591980.


# Proposed approach

- Intraoperative analysis of resection margin in real-time at OR (without a pathologist)
- Injecting PSMA (Prostate Specific Membrane Antigen) based tracers into the tissue for precise targeting of prostate cancer cells
- 3D reconstruction volume of the sample using **RGB-D** camera
- **SPECT** for detecting the resection margin of the sample
- **Registration** of SPECT data in the 3D volume
- Accuracy can be enhanced by using a hybrid tracer (SPECT + Fluorescence tracer, Ex: 99mTc-EuK-(SO3)Cy5-mas3) [8]
- Thus, the proposed solution would be a **hybrid specimen analyzer using SPECT and** fluorescence imaging






# Proposed approach - "system overview"



# **RGB-D task overview**





Step 1: Data (Gamma ray) acquisition using CrystalCam



Step 2: Formation of linear set of equations

[Source/Courtesy: Crystal Photonics GmbH]

$$y = Ax$$

Where, y = Physical measurements

A = System matrix (Each row corresponds to one measurement in our system; Each column represents the different contributions of a particular voxel to the results on each measurement)

x = Quantity we want to reconstruct

<u>Step 3:</u> Solving the linear system of equations using MLEM (Maximum Likelihood Expectation Maximization)


$$x_i^{k+1} = x_i^k \cdot \frac{1}{\sum\limits_{j=0}^{J} a_{ij}} \cdot \sum\limits_{j=0}^{J} \frac{y_j \cdot a_{ij}}{q_j}$$

$$q_j = \sum_{i=0}^{I} x_i^k \cdot a_{ij}$$


Slide 17




<u>Step 3:</u> Solving the linear system of equations using MLEM (Maximum Likelihood Expectation Maximization)




<u>Step 3:</u> Solving the linear system of equations using MLEM (Maximum Likelihood Expectation Maximization)



<u>Step 3:</u> Solving the linear system of equations using MLEM (Maximum Likelihood Expectation Maximization)



# **Timeline & Conclusion 1.1**








# **Initial results / Conclusion 1.2**

- Need for the system is high and thus the market potential.
- Research community is very active in this intra-operative field. [6]
- Recent introduction of PSMA based tracers would help us in precise targeting of prostate cells [10]
  Trend of Publications of PSMA-targeting Small Molecule Ligands and Antibody Conjugates over 20 Years



### (Publications on PSMA-targeting tracers since 2002)

[6] Heidkamp J, Scholte M, Rosman C, Manohar S, Fütterer JJ, Rovers MM. Novel imaging techniques for intraoperative margin assessment in surgical oncology: A systematic review. Int J Cancer. 2021 Aug 1;149(3):635-645. doi: 10.1002/ijc.33570. Epub 2021 May 4. PMID: 33739453; PMCID: PMC8252509.

[10] Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. J Nucl Med. 2022 Apr;63(4):567-572. doi: 10.2967/jnumed.121.262412. Epub 2021 Jul 29. PMID: 34326126; PMCID: PMC8973291.



